August 22, 2019
|
November 13, 2019
|
December 27, 2023
|
January 13, 2021
|
June 2024 (Final data collection date for primary outcome measure)
|
- Safety Measured by Incidence and Severity of Adverse Events 24 hrs post-dose [ Time Frame: approximately Week 1 ]
In participants with OUD, the safety of this intervention will be assessed by characterize adverse events associated with adding two psilocybin doses to a stable buprenorphine regimen.
- Safety Measured by Incidence and Severity of Adverse Events 24 hrs post-dose [ Time Frame: approximately Week 5 ]
In participants with OUD, the safety of this intervention will be assessed by characterizing adverse events associated with adding two psilocybin doses to a stable buprenorphine-naloxone regimen.
- Mean Change in Symptoms of Opioid Withdrawal Measured by COWS Instrument [ Time Frame: up to 5 weeks ]
It is hypothesized that co-administration of oral psilocybin with a buprenorphine-naloxone formulation will not cause signs and symptoms of opioid withdrawal. This will be measured by the Clinical Opiate Withdrawal Scale (COWS) instrument, an 11-item scale administered by the clinician where total score of: 5- 12 = mild withdrawal; 13-24 = moderate withdrawal; 25-36 = moderately severe withdrawal; and more than 36 = severe withdrawal. Administered before the dose and again 8 hours after the dose.
- Mean Change in Peripheral Capillary Oxygen [ Time Frame: up to 5 weeks ]
It is hypothesized that co-administration of oral psilocybin with a buprenorphine-naloxone formulation will not cause opioid intoxication. Opioid intoxication will be determined by drops peripheral capillary oxygen saturation (SpO2) before and after dosing.
- Mean Change in ECG [ Time Frame: up to 5 weeks ]
It is hypothesized that co-administration of oral psilocybin with a buprenorphine-naloxone formulation will not cause a clinically significant increase in the QTc interval. The QTc interval will be measured by electrocardiogram (ECG) before and after dosing. If a QTc(F), calculated by the CardioCard system exceeds 470msec, a study physician will be contacted immediately for further monitoring and treatment recommendations.
|
- Safety Measured by Incidence and Severity of Adverse Events 24 hrs post-dose [ Time Frame: approximately Week 1 ]
In participants with OUD in early or sustained full recovery on buprenorphine/naloxone therapy, the safety of this intervention will be assessed by characterize adverse events associated with adding two psilocybin doses to a stable buprenorphine/naloxone regimen.
- Safety Measured by Incidence and Severity of Adverse Events 24 hrs post-dose [ Time Frame: approximately Week 5 ]
In participants with OUD in early or sustained full recovery on buprenorphine/naloxone therapy, the safety of this intervention will be assessed by characterize adverse events associated with adding two psilocybin doses to a stable buprenorphine/naloxone regimen.
- Mean Change in Symptoms of Opioid Withdrawal Measured by COWS Instrument [ Time Frame: up to 5 weeks ]
It is hypothesized that co-administration of oral psilocybin with buprenorphine/naloxone will not cause signs and symptoms of opioid withdrawal. This will be measured by the Clinical Opiate Withdrawal Scale (COWS) instrument, an 11-item scale administered by the clinician where total score of: 5- 12 = mild withdrawal; 13-24 = moderate withdrawal; 25-36 = moderately severe withdrawal; and more than 36 = severe withdrawal. Administered before the dose and again 8 hours after the dose.
- Mean Change in Peripheral Capillary Oxygen [ Time Frame: up to 5 weeks ]
It is hypothesized that co-administration of oral psilocybin with buprenorphine/naloxone will not cause opioid intoxication. Opioid intoxication will be determined by drops peripheral capillary oxygen saturation (SpO2) before and after dosing.
- Mean Change in ECG [ Time Frame: up to 5 weeks ]
It is hypothesized that co-administration of oral psilocybin with buprenorphine/naloxone will not cause a clinically significant increase in the QTc interval. The QTc interval will be measured by electrocardiogram (ECG) before and after dosing. ECGs will be collected using the CardioCard PC computer-based system, once before the dose, and again at 1, 2, 3, 4, 6, and 8 hours after the dose. If a QTc(F), calculated by the CardioCard system exceeds 470msec, a study physician will be contacted immediately for further monitoring and treatment recommendations.
|
|
- Change in Opioid Craving Scale (OCS) from baseline through end of study [ Time Frame: Baseline, Week 1, Week 5, and Week 9 ]
To evaluate the effect of psilocybin treatment on the effectiveness of buprenorphine-naloxone maintenance therapy. The hypothesis is that co-administration of oral psilocybin with a buprenorphine-naloxone formulation will not cause an increase in opioid craving, as measured by the OCS at baseline, week 1, week 5, and week 9. The OCS is a 3-item visual analog scale to measure the frequency and intensity of opioid craving. Total score ranges from 0-30 where the higher the number, the higher the craving.
- Mean Number of Days of Participant Opioid Use via Time Line Follow Back (TLFB) [ Time Frame: up to 9 weeks ]
It is hypothesized that co-administration of oral psilocybin with a buprenorphine-naloxone formulation will not be associated with an increase in self-reported illicit opioid use. This will be measured by Time Line Follow-Back calendar method for up to the 28 days following the last dosing session. Participants will be asked to recall the previous 28 days of substance use at the first in-person visit.
|
- Change in Opioid Craving Scale (OCS) from baseline through end of study [ Time Frame: Baseline, Week 1, Week 5, and Week 9 ]
To evaluate the effect of psilocybin treatment on the effectiveness of buprenorphine/naloxone maintenance therapy. The hypothesis is that co-administration of oral psilocybin with buprenorphine/naloxone will not cause an increase in opioid craving, as measured by the OCS at baseline, week 1, week 5, and week 9. The OCS is a 3-item visual analog scale to measure the frequency and intensity of opioid craving. Total score ranges from 0-30 where the higher the number, the higher the craving.
- Mystical Effects Questionnaire (MEQ) after each dose [ Time Frame: approximately Week 1 and Week 5 ]
To evaluate the effect of concurrent buprenorphine/naloxone use on the effects of psilocybin therapy. The hypothesis is that co-administration of buprenorphine/naloxone with oral psilocybin will not be associated with a change in the effects of psilocybin, as measured by adverse events (Primary Outcome Measure), and the MEQ. The MEQ is a 30-item assessment used to characterize the consciousness-altering effects of psilocybin. Total possible range of scores is 0-150 where the higher the number the higher the consciousness-altering effects.
- Mean Number of Days of Participant Opioid Use via Time Line Follow Back (TLFB) [ Time Frame: up to 9 weeks ]
It is hypothesized that co-administration of oral psilocybin with buprenorphine/naloxone will not be associated with an increase in self-reported illicit opioid use. This will be measured by Time Line Follow-Back calendar method for up to the 28 days following the last dosing session. Participants will be asked to recall the previous 28 days of substance use at the first in-person visit.
|
Not Provided
|
- Change in Participant Generalized Self-Efficacy Scale (GSES) [ Time Frame: Baseline and End of Study, Up to 9 weeks ]
Descriptive changes in participant self-efficacy, quality of life, and pain will be explored through a number of participant surveys.
The GSES is a 10-item scale to assess a participants self-beliefs to cope with difficult situations. The total range of possible scores is 10-40, higher scores indicate more self-efficacy.
- Change in The Meaning in Life Questionnaire (TMQ) [ Time Frame: Baseline and End of Study, Up to 9 weeks ]
Descriptive changes in participant self-efficacy, quality of life, and pain will be explored through a number of participant surveys.
TMQ is a 10-item questionnaire designed to measure how much participants feel their lives have meaning and how much they strive to find meaning and understanding in their lives. Items are scored on a 7-point Likert Scale from 1 (absolutely true) to 7 (absolutely untrue). Item 9 is reverse scored. The total range of possible scores is 10-70, higher scores indicate more perceived meaning in life.
- Change in The Gratitude Questionnaire (TGQ) [ Time Frame: Baseline and End of Study, Up to 9 weeks ]
Descriptive changes in participant self-efficacy, quality of life, and pain will be explored through a number of participant surveys.
TGQ is a 6-item questionnaire measures levels of dispositional gratitude. Items are scored on a 7-point Likert Scale from 1 (strongly disagree) to 7 (strongly agree). Items 3 and 6 are reverse scored. The total range of possible scores is 6-42, higher scores indicate more gratitude.
- Change in Brief Pain Inventory (BPI) [ Time Frame: Baseline and End of Study, Up to 9 weeks ]
Descriptive changes in participant self-efficacy, quality of life, and pain will be explored through a number of participant surveys.
BPI is a 9-item questionnaire designed to rapidly assess the severity of pain and its impact on functioning. Higher scores (0-10) indicate higher perceived pain.
|
|
Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine
|
Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation
|
Primary Aim: In participants with OUD, to characterize adverse events associated with adding two psilocybin doses to a stable buprenorphine-naloxone formulation.
Secondary Aim: To evaluate the effect of psilocybin treatment on the effectiveness of a buprenorphine-naloxone maintenance therapy.
Secondary Aim: To evaluate the effect of concurrent buprenorphine-naloxone use on the effects of psilocybin therapy.
Descriptive Aim: To describe any changes in self-efficacy, quality of life, pain.
|
The primary objective of this clinical trial is to determine the safety of psilocybin in adult patients with opioid use disorder concurrently taking buprenorphine-naloxone.
Eligible participants will be adults with active opioid use disorder (OUD) who are willing to begin and maintain a daily dose of buprenorphine-naloxone throughout study participation. Initiation, stabilization, and maintenance of buprenorphine-naloxone will be overseen by a qualified study medical provider. After psychological screening and at least 6 hours of preparatory counseling and preparation for the psilocybin dosing, set, and setting, each participant will ingest 1 oral dose of psilocybin. All dosing sessions will be attended by 2 specially trained facilitators, in a dedicated Clinical Research Facility. After eight hours of observation in the dosing room, the participant will be kept overnight in the hospital Clinical Research Unit, and complete an integration session with a psychologist before discharge to home. Approximately 4 weeks after the first dose, the participant will receive a second oral dose of psilocybin, with the same length of observation.
Participants who have been administered the first dose but decline to receive the second dose will remain evaluable. At study termination, their active study participation will end, but completion of the 28 day post-dose follow up will be requested.
The primary endpoint is the assessment of the safety of concurrent administration of a buprenorphine-naloxone formulation and psilocybin as determined by physiological measures (ECG, respiratory rate, blood pressure, body temperature, and blood oxygen saturation) and validated clinical and self-report measures (Clinical Opiate Withdrawal Scale (COWS), Opioid Craving Scale (OCS), Timeline Follow-Back (TLFB)).
If you are interested in participating in this study, please fill out a brief 1-minute survey at the link in the "More Information" section at the bottom of this record.
|
Interventional
|
Phase 1
|
Allocation: N/A Intervention Model: Single Group Assignment Intervention Model Description: open-label pilot study Masking: None (Open Label) Primary Purpose: Health Services Research
|
Opioid Use Disorder
|
Drug: Psilocybin with facilitated counseling
open-label pilot study
|
Experimental: Open-label
Psilocybin with facilitated counseling: Psilocybin will be administered in the form of capsules, taken orally with water. Each participant will receive 2 doses, approximately 4 weeks apart.
Intervention: Drug: Psilocybin with facilitated counseling
|
Not Provided
|
|
Recruiting
|
10
|
Same as current
|
June 2024
|
June 2024 (Final data collection date for primary outcome measure)
|
Inclusion Criteria:
Exclusion Criteria:
- Currently prescribed and has taken buprenorphine or buprenorphine formulation (e.g., Suboxone®) for over four weeks immediately prior to initial study contact
- Currently receiving pharmacotherapy of any duration with methadone
- Current participation in a drug treatment court program or other legal supervision. Individuals who are under legal supervision will be advised that participating in this study could potentially violate terms of probation, parole, or extended supervision. Contact information for the individual's community supervision officer must be collected to confirm whether study participation may impact the potential participant's status on probation or parole
- Inadequately treated hypertension
- Current acute coronary syndrome or angina
- Evidence of ischemic disease, cardiac conduction defects, and/or ventricular arrhythmias on screening ECG
- History of heart transplant
- Current insulin dependence, due to Type I or Type II diabetes
- Urine drug test containing non-prescribed drugs of abuse
- Any finding(s), based on the screening process, that the PI feels makes the study unsuitable for the participant
|
Sexes Eligible for Study: |
All |
|
21 Years to 65 Years (Adult, Older Adult)
|
No
|
|
United States
|
|
|
NCT04161066
|
2019-0187 A532007 ( Other Identifier: UW Madison ) SMPH/FAMILY MEDICINE ( Other Identifier: UW Madison ) Protocol Version 9/22/2023 ( Other Identifier: UW Madison )
|
Yes
|
Studies a U.S. FDA-regulated Drug Product: |
Yes |
Studies a U.S. FDA-regulated Device Product: |
No |
|
Plan to Share IPD: |
No |
Plan Description: |
No individual participant data sharing is planned |
|
University of Wisconsin, Madison
|
Same as current
|
University of Wisconsin, Madison
|
Same as current
|
- Heffter Research Institute
- Etheridge Foundation
|
Principal Investigator: |
Randall Brown, MD PhD |
University of Wisconsin, Madison |
|
University of Wisconsin, Madison
|
July 2023
|